Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01137994
Other study ID # 113333
Secondary ID
Status Withdrawn
Phase Phase 2
First received June 3, 2010
Last updated March 11, 2013
Start date October 2011
Est. completion date March 2018

Study information

Verified date March 2013
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase II, randomized, open-label, multi-center study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women with HER2-positive and p95HER2-positive metastatic breast cancer (MBC). Eligible subjects will have newly diagnosed metastatic breast cancer (Stage IV) either as a primary diagnosis or as a recurrence following treatment of curative intent; not have received systemic or local treatment for MBC and have breast cancer that is positive for HER2 and p95HER2. The primary objective is to compare progression-free survival (PFS) of lapatinib plus chemotherapy versus trastuzumab plus chemotherapy as first-line treatment in subjects with MBC exhibiting concurrent HER2 overexpression (and/or gene amplification) and expression of carboxy-terminal fragments of HER2 (p95HER2). The secondary objectives are to evaluate overall survival, overall response rate, clinical benefit response rate and the safety as well as tolerability of lapatinib plus chemotherapy and trastuzumab plus chemotherapy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2018
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female = 18 years of age

- Histologically or cytologically confirmed invasive breast cancer with distant metastasis(ses) (designated as Stage IV or metastatic breast cancer)

- Diagnosis with Stage IV or metastatic disease at either primary diagnosis or recurrence

- Not received prior systemic or local treatment (e.g., chemotherapy, endocrine or radiotherapy) for Stage IV/metastatic breast cancer

- Prior adjuvant and/or neo-adjuvant therapy is permitted

- Documentation of HER2 overexpression or gene amplification, in the invasive component of either a metastatic disease site or primary tumor, defined as: 3+ by IHC and/or HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization [FISH, CISH or SISH; >6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of =2.0]

- Documentation by the central laboratory of positive p95HER2 expression in the invasive component of either a metastatic disease site (preferred) or primary tumor

- No history of CNS metastases (including leptomeningeal involvement) or stable CNS metastases (defined as asymptomatic and off steroids for = 3 months)

- Baseline Left Ventricular Ejection Fraction (LVEF) =50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)

- Recovered or stabilized from all adverse events associated with prior anti-cancer therapies, including radiotherapy, at the time of screening

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

- Have adequate marrow and organ function as defined as:

SYSTEM LABORATORY VALUES Hematologic ANC =1.5 x 109/L Hemoglobin =9 g/dL (after transfusion if needed) Platelets =100 x 109/L Hepatic Albumin = 2.5 g/dL Serum bilirubin =1.5 x ULN unless due to Gilbert's syndrome AST and ALT =3 x ULN Renal Calculated creatinine clearance = 40 mL/min Serum Creatinine =1.5 mg/dL or 132.6µmol/L (Abbreviations: ANC, absolute neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase)

- Women of childbearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) must have a negative serum pregnancy test and agree to use effective contraception, as defined in protocol

- Signed Informed Consent Form

Exclusion Criteria:

- History of other malignancy. Exception: Subjects who have been disease-free for 5 years or subjects with a history of completely resected non-melanoma skin cancer (basal or squamous) are eligible

- Concurrent anti-cancer treatment or concurrent treatment with an investigational drug

- Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment

- Prior treatment with anti-HER2 therapy, except trastuzumab or lapatinib (time from last dose of trastuzumab or lapatinib to randomization must be =3 months)

- Serious cardiac illness or medical condition including but not confined to:

- Uncontrolled arrhythmias

- Uncontrolled or symptomatic angina

- History of congestive heart failure (CHF)

- Documented myocardial infarction <6 months from study entry

- Current active hepatic or biliary disease (with exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)

- Concurrent disease or condition, or any pre-existing medical disorder that in the opinion of the investigator may interfere with the subject's safety, obtaining informed consent or compliance to the study procedures

- Pregnant or lactating female

- Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels (consult with GSK Medical Monitor if uncertain about eligibility)

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their excipients that, in the opinion of the investigator contra-indicates participation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lapatinib
oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
Biological:
Trastuzumab
monoclonal antibody directed to HER2 receptor
Drug:
Docetaxel
Taxane chemotherapy
Paclitaxel
Taxane chemotherapy
Vinorelbine
Vinka alkaloid

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival Time from randomization to disease progression No
Secondary Overall Survival end of study No
Secondary Overall response rate (ORR: complete response [CR] or partial response [PR]) end of study No
Secondary Clinical benefit response rate (CBR: CR or PR at any time, or stable disease [SD] >=24 weeks end of study No
Secondary Safety and tolerability of lapatinib plus chemotherapy and trastuzumab plus chemotherapy end of study No
See also
  Status Clinical Trial Phase
Terminated NCT00251433 - GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer Phase 1
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Recruiting NCT04892342 - Study of ESG401 in Adults With Solid Tumors Phase 1/Phase 2
Terminated NCT02213042 - Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Phase 2
Completed NCT00790816 - Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents Phase 1
Completed NCT00051103 - Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. Phase 2
Completed NCT00320411 - GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer Phase 2
Completed NCT00258050 - To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients Phase 1
Terminated NCT01498588 - Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Phase 2
Terminated NCT00479856 - Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer Phase 2
Completed NCT00320385 - Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Phase 3
Completed NCT00062686 - GW572016 For Treatment Of Refractory Metastatic Breast Cancer Phase 2
Completed NCT00996762 - A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Phase 1
Terminated NCT02913729 - Pre- Versus Postoperative Accelerated Partial Breast Irradiation N/A
Completed NCT01160211 - A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Phase 3
Recruiting NCT05814224 - Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA N/A
Completed NCT01815294 - A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer Phase 1
Terminated NCT00437073 - Brain Metastases In ErbB2-Positive Breast Cancer Phase 2
Completed NCT00356811 - Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer Phase 2
Completed NCT00490139 - ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Phase 3